Zobrazeno 1 - 10
of 1 234
pro vyhledávání: '"David J. Posey"'
Autor:
Christopher J. McDougle, Robyn P. Thom, Caitlin T. Ravichandran, Michelle L. Palumbo, Laura C. Politte, Jennifer E. Mullett, Christopher J. Keary, Craig A. Erickson, Kimberly A. Stigler, Lauren Mathieu-Frasier, David J. Posey
Publikováno v:
Neuropsychopharmacology
This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3932aef9a75c7e2548e6dd8557d4d97
https://europepmc.org/articles/PMC9019024/
https://europepmc.org/articles/PMC9019024/
Autor:
Bhavik Shah, Erika L. Nurmi, Fiona Whelan, Lawrence Scahill, L. E. Arnold, K. K. Badashova, Benedetto Vitiello, Mark Davies, Christopher J. McDougle, Shirley Chuang, David J. Posey, James T. McCracken, Elaine Tierney, Michael G. Aman
Publikováno v:
The Pharmacogenomics Journal
The pharmacogenomics journal, vol 14, iss 3
The pharmacogenomics journal, vol 14, iss 3
Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as i
Autor:
Christopher J. McDougle, Ryan Adams, David J. Posey, Logan K. Wink, James E. Klaunig, Zemin Wang, Craig A. Erickson, Martin H. Plawecki
Publikováno v:
Molecular Autism
Background Social impairment is a defining feature of autism spectrum disorder (ASD) with no demonstrated effective pharmacologic treatments. The goal of this study was to evaluate efficacy, safety, and tolerability of oral N-acetylcysteine (NAC), an
Autor:
Randall L. Caldwell, Kimberly A. Stigler, Danielle K. Orsagh-Yentis, Craig A. Erickson, Christopher J. McDougle, David J. Posey, Jason G. Ho
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 22:277-283
Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorde
Autor:
Kimberly A. Stigler, Craig A. Erickson, Christopher J. McDougle, Jennifer E. Mullett, David J. Posey
Publikováno v:
Psychopharmacology. 223:237-245
Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more
Autor:
Logan K. Wink, Christopher J. McDougle, Craig A. Erickson, Arlene E. Kohn, David J. Posey, Kimberly A. Stigler, Jennifer E. Mullett
Publikováno v:
Psychopharmacology. 216:85-90
Fragile X syndrome (FXS) is the most common inherited form of developmental disability and most common single gene cause of autism. Persons with FXS frequently exhibit irritable behavior marked by aggression, self-injury, and severe tantrums. Despite
Autor:
Christopher J. McDougle, David J. Posey, Kelly Blankenship, Craig A. Erickson, Kimberly A. Stigler
Publikováno v:
Pediatric Health. 4:375-381
Aripiprazole was recently US FDA-approved to treat irritability in children and adolescents with autistic disorder aged 6–17 years. There are currently only two psychotropics approved by the FDA to treat irritability in the autistic population. Thi
Autor:
Kimberly A. Stigler, Christopher J. McDougle, Jennifer E. Mullett, David J. Posey, Craig A. Erickson
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 20:75-78
Publikováno v:
Research in Autism Spectrum Disorders. 3:840-860
Cases of autistic disorder (autism) have frequently been reported in association with congenital rubella and other infections. These observations stimulated further investigation into markers of immune function in autism. Postinfectious and autoimmun
Autor:
Kimberly A. Stigler, Arlene E. Kohn, Christopher J. McDougle, David J. Posey, Jonathan T. Diener, Craig A. Erickson, Lang Li
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 19:265-274
The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder.This is a 14-week, prospective, open-label invest